Sildenafil - Alvogen Korea

Drug Profile

Sildenafil - Alvogen Korea

Alternative Names: KW 25084

Latest Information Update: 03 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KunWha Pharmaceutical
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Erectile dysfunction

Most Recent Events

  • 03 Jun 2016 Chemical structure information added
  • 15 Mar 2016 Biomarkers information updated
  • 01 Jun 2015 Phase-I clinical trials in Erectile dysfunction (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top